Rapid effectiveness of eptinezumab to treat ongoing migraine attacks: preliminary data from an Italian multicenter real-world experience (the BE-FREE study).

Front Neurol · 2026 · PMC13076166 · PMID 41988493

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

a significant trendp = 0.056so close (0.05 < p ≤ 0.1)

The NRS score significantly decreased from T0 (7.0, IQR: 2) to T10 (6.0, IQR: 3; p = 0.011) and from T10 to T20 (5.0, IQR: 3; p = 0.004), with a significant trend also from T20 to T30 (5.0, IQR: 5; p = 0.056).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.